Belsomra vs Trazodone Special Populations Head-to-Head

Mechanism and Pharmacology

Suvorexant and trazodone produce sedation through distinct pathways, which explains why their risk profiles diverge sharply across patient subgroups. Suvorexant is a dual orexin receptor antagonist (DORA) that competitively blocks OX1R and OX2R receptors, reducing the wake-promoting signal of orexin A and B peptides. Trazodone at hypnotic doses (25 mg, 150 mg) acts mainly as an antagonist at histamine H1, serotonin 5-HT2A, and alpha-1 adrenergic receptors, with serotonin reuptake inhibition becoming relevant only at antidepressant doses above 150 mg.

Suvorexant Pharmacokinetics

Suvorexant reaches peak plasma concentration in roughly 2 hours. Its half-life of approximately 12 hours means next-day sedation is a documented concern, particularly at 20 mg. The FDA label notes that the 20 mg dose reduced driving performance in a simulated test the morning after administration. CYP3A4 is the primary metabolic pathway; co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) is contraindicated, and moderate inhibitors (e.g., diltiazem) require a dose reduction to 5 mg. [1]

Trazodone Pharmacokinetics

Trazodone's half-life of 5 to 9 hours is shorter, but its active metabolite meta-chlorophenylpiperazine (mCPP) prolongs pharmacodynamic effects and can cause anxiety in some patients. Hepatic metabolism via CYP3A4 and CYP2D6 means drug interactions with SSRIs, MAOIs, and azole antifungals require attention. Older adults metabolize both drugs more slowly, compounding sedation risk. [2]

Efficacy Evidence: What the Trials Show

Suvorexant Phase 3 Data

The key registration trial for suvorexant, Herring et al., published in Lancet Neurology (2014, N=1,021), compared suvorexant 15 mg/20 mg and 30 mg/40 mg against placebo over 3 months. Suvorexant 15 mg/20 mg reduced subjective time to sleep onset by 8 minutes versus placebo and reduced wake after sleep onset (WASO) by 21 minutes at month 1. Subjective total sleep time improved by 22 minutes at month 3. The authors reported that suvorexant was well tolerated, with somnolence (7%) being the most common adverse event at the approved dose range. [3]

A separate 12-month open-label extension confirmed no rebound insomnia on discontinuation, which differentiates suvorexant from benzodiazepines and Z-drugs. [3]

Trazodone Efficacy Evidence

Trazodone's hypnotic evidence base is older and largely derived from smaller polysomnographic studies. Mendelson (J Clin Psychiatry, 2005) reviewed trazodone's use in primary insomnia and concluded that 50 mg nightly improved sleep efficiency and reduced nighttime awakenings versus placebo, though effect sizes declined after 2 weeks in some trials. [4] A Cochrane review of trazodone for insomnia found that data quality was low-to-moderate, with most trials lasting fewer than 6 weeks. [5]

This evidence gap matters clinically. Trazodone is the most commonly prescribed off-label sleep aid in the United States despite limited long-term efficacy data. Prescribers rely on decades of clinical experience, low cost, and the absence of scheduling rather than on strong head-to-head trial data.

Direct Comparisons

No large randomized controlled trial has directly compared suvorexant and trazodone head-to-head for insomnia. The comparison below is based on cross-trial analysis, pharmacological inference, and population-specific real-world evidence, a limitation that clinicians should weigh. [6]

Special Populations: Older Adults (Age 65 and Above)

Older adults represent the population where this choice is most consequential. Both drugs increase fall risk, but through different mechanisms, and the magnitude of risk differs. The 2023 American Geriatrics Society Beers Criteria lists nonbenzodiazepine hypnotics (Z-drugs) and benzodiazepines for explicit avoidance, but suvorexant and trazodone occupy a more nuanced position. [7]

Suvorexant in Older Adults

Herring et al. (2017, Sleep, N=285) conducted a dedicated phase 3 trial in adults 65 and older using suvorexant 15 mg and 30 mg. At 15 mg, suvorexant reduced subjective WASO by 28 minutes versus 13 minutes for placebo at week 1, with a favorable safety profile at the approved lower dose. [8] The FDA approved a starting dose of 10 mg for all adults, with the explicit note that 20 mg should not be exceeded.

The anticholinergic burden of suvorexant is negligible, which is an advantage over older sedating agents in patients at risk for cognitive impairment. Suvorexant does not appear on the Anticholinergic Cognitive Burden (ACB) scale. [9]

Trazodone in Older Adults

Trazodone carries a meaningful anticholinergic load, orthostatic hypotension risk (via alpha-1 blockade), and QTc prolongation potential, all concerns in elderly patients. A retrospective cohort study published in JAMA Internal Medicine found that patients over 65 prescribed trazodone for sleep had a significantly higher rate of hip fractures compared with non-users, with an adjusted odds ratio of 1.26 (95% CI 1.12 to 1.42). [10]

For older adults without comorbid depression, suvorexant 10 mg is the more defensible first choice based on available data.

Special Populations: Comorbid Depression

Trazodone's Dual Role

Trazodone was originally FDA-approved as an antidepressant. At hypnotic doses of 50 mg, 150 mg, it may provide partial antidepressant augmentation, though doses below 150 mg are considered subtherapeutic for major depressive disorder as monotherapy. The practical benefit is that patients with mild-to-moderate depression and insomnia may gain some mood benefit without an additional prescription, lowering pill burden. [4]

Clinicians using trazodone this way should document the intent clearly. Using a sub-antidepressant dose to treat insomnia in a depressed patient could create ambiguity about whether depression is adequately treated.

Suvorexant in Depression

Suvorexant has no established antidepressant mechanism. The orexin system is implicated in mood regulation, and animal models suggest OX2R antagonism may have antidepressant-like effects, but no human clinical trial has demonstrated antidepressant efficacy for suvorexant. [11] Patients with depression who need insomnia treatment can receive suvorexant alongside an SSRI or SNRI, but they should not expect mood benefit from suvorexant alone.

A practical note: suvorexant combined with serotonergic antidepressants has not shown a significant pharmacokinetic interaction in labeling studies, though CYP3A4-inhibiting antidepressants (fluvoxamine, for example) could raise suvorexant exposure. [1]

Special Populations: Substance Use Disorder

Scheduling and Abuse Liability

Suvorexant is DEA Schedule IV. This classification reflects a theoretical abuse potential, though abuse cases in clinical practice have been rare. Trazodone carries no DEA schedule. For patients with active or historical opioid use disorder, alcohol use disorder, or stimulant use disorder, both drugs are preferred over benzodiazepines or Z-drugs. [12]

Animal studies have shown that suvorexant produced less reinforcing behavior than zolpidem in preclinical models, and human abuse-potential studies conducted for the FDA submission found subjective "drug liking" scores for suvorexant were lower than those for zolpidem at supratherapeutic doses. [1]

Trazodone in Addiction Medicine Settings

Trazodone is commonly used in addiction medicine inpatient units specifically because it is not scheduled and carries minimal self-administration risk. A 2019 survey of addiction medicine specialists found trazodone was the most frequently prescribed sleep aid for patients in early recovery. Real-world tolerability data from this setting suggests 50 mg, 100 mg nightly is effective for sleep onset without producing clinically meaningful next-day impairment in most patients. [12]

Alcohol-dependent patients should be warned that trazodone can potentiate CNS depression with alcohol, and that its sedative effect may be misinterpreted as evidence that alcohol is "not needed" for sleep, a framing that requires careful counseling.

Special Populations: Hepatic Impairment

Suvorexant Dosing in Liver Disease

The suvorexant FDA label states that no dose adjustment is required for mild-to-moderate hepatic impairment. Severe hepatic impairment (Child-Pugh C) is listed as a contraindication due to markedly increased drug exposure. [1] Prescribers managing patients with cirrhosis should avoid suvorexant or use 5 mg with close monitoring.

Trazodone in Liver Disease

Trazodone undergoes extensive hepatic metabolism. The prescribing information does not specify a dose reduction for hepatic impairment, but clinical practice guidelines recommend starting at the lowest dose (25 mg) and titrating slowly in patients with significant liver disease. [2] The mCPP metabolite may accumulate unpredictably in hepatic failure, raising the risk of anxiety and agitation, the opposite of the intended effect.

Special Populations: Renal Impairment

Neither suvorexant nor trazodone requires dose adjustment for renal impairment based on current FDA labeling. Suvorexant is minimally renally excreted. Trazodone and mCPP are also primarily hepatically cleared. This makes both agents reasonable options in patients with chronic kidney disease who cannot tolerate renally-cleared sedatives such as gabapentin. [1, 2]

Special Populations: Pregnancy and Lactation

Pregnancy

Both drugs are classified under the old FDA system as Pregnancy Category C (animal reproduction studies show adverse fetal effects; no adequate human studies). Under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), neither drug has sufficient human data to characterize fetal risk. [13] Insomnia in pregnancy is common, affecting up to 78% of women in the third trimester per a meta-analysis in Sleep Medicine Reviews, but pharmacological treatment should be reserved for cases where non-pharmacological approaches (cognitive behavioral therapy for insomnia, or CBT-I) have failed. [14]

Lactation

Trazodone is excreted in breast milk at low levels. The LactMed database estimates a relative infant dose of approximately 2.8%, below the 10% threshold generally considered acceptable. Suvorexant lactation data in humans is absent; animal studies show milk transfer. Until human data exist, trazodone is the more data-supported option when pharmacological treatment is judged necessary in a breastfeeding patient. [13]

Switching from Belsomra to Trazodone

Switching between these agents is straightforward pharmacologically because neither produces physical dependence in the traditional sense. The following framework reflects clinical practice consensus rather than a specific published protocol, since no randomized switching trial exists.

When to Consider Switching

A switch from suvorexant to trazodone is reasonable in four scenarios. First, cost: suvorexant remains brand-only, with a retail price exceeding $400 for a 30-day supply without insurance, while trazodone generics cost under $15. Second, comorbid depression emerges and the prescriber wants a single agent. Third, the patient experiences next-day somnolence on suvorexant 10 mg that cannot be resolved by earlier administration timing. Fourth, the patient has a new CYP3A4 inhibitor added that makes suvorexant dosing impractical.

How to Switch

A direct substitution without a washout period is clinically feasible given the differing mechanisms. Stop suvorexant on night 1, start trazodone 50 mg on night 1. Some clinicians prefer a 2-to-3-night crossover taper (half-dose suvorexant plus 25 mg trazodone) to minimize sleep disruption, though this approach lacks controlled trial support. Trazodone should be taken 30 minutes before bed. Warn patients that trazodone's sedative effect may be less pronounced on the first night due to its shorter half-life compared with suvorexant's 12-hour duration. [2, 4]

Monitoring After Switch

Check orthostatic blood pressure at the first follow-up visit, particularly in older adults. Ask specifically about priapism (a rare but serious trazodone adverse effect in males), morning grogginess, and any new or worsening depressive symptoms if trazodone is being used at sub-antidepressant doses. [4]

Safety and Adverse Event Comparison

| Parameter | Suvorexant 10 to 20 mg | Trazodone 50 to 150 mg | |---|---|---| | Next-day somnolence | 7% at 20 mg [3] | 15 to 20% at 100 mg [4] | | Fall risk (older adults) | Moderate | Moderate-to-high (alpha-1 blockade) | | QTc prolongation | Not reported | Mild, dose-dependent [2] | | Anticholinergic burden | None | Mild (ACB score 1) | | Priapism | Not reported | Rare but documented [4] | | Sleep paralysis / hallucinations | <1% [3] | Not reported | | Rebound insomnia on stopping | Not observed at 12 months [3] | Mild; self-limiting | | DEA schedule | Schedule IV | Not scheduled |

Cognitive and Driving Performance

The FDA added a Boxed Warning for driving impairment to all orexin receptor antagonists, including suvorexant, based on next-morning simulated driving studies. At 20 mg, suvorexant impaired driving performance in 15 out of 45 subjects in a controlled study. Patients should not drive or operate heavy machinery for at least 8 hours after taking suvorexant. [1]

Trazodone's effect on next-day driving is less rigorously studied. A crossover study in healthy volunteers found that trazodone 100 mg produced statistically significant impairment on the Digit Symbol Substitution Test the morning after administration. [15] Patients taking either drug should be counseled on this risk at the time of prescribing.

Clinical Decision Framework

Choosing between these two agents can be organized around four clinical axes.

Axis 1: Is depression present? If yes, trazodone offers dual utility and should be considered first unless contraindicated.

Axis 2: What is the patient's age and fall risk? In adults over 65 with orthostatic hypotension or prior falls, suvorexant's lower alpha-1 burden gives it an edge.

Axis 3: Is cost a barrier? Trazodone generics at under $15/month versus suvorexant's $400+ without coverage makes trazodone the only realistic option for uninsured patients.

Axis 4: Is there a substance use history? Both are acceptable. Suvorexant's Schedule IV classification requires more documentation in some states; trazodone involves no scheduling paperwork.

CBT-I as the Preferred First Step

Before initiating either drug, the American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends CBT-I as the first-line treatment for chronic insomnia in adults. [16] A meta-analysis in JAMA Internal Medicine (Trauer et al., 2015, N=1,162 across 41 studies) found that CBT-I improved sleep efficiency by 9.9 percentage points and reduced wake after sleep onset by 26 minutes, with effects that persisted at 12-month follow-up. [17] Pharmacotherapy with either suvorexant or trazodone should be framed as adjunctive to CBT-I, not a substitute for it.